MYD88 and lymphoma: MYD88, CD79B, and other NF-κB-pathway-related mutations promote IL-10 expression by lymphoma cells [15, 16, 20], and IL-10 has also been found to express in CD68+ and CD163+ tumor-associated macrophages by double immunostaining analysis [21].